Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14444655 | 0.95 | PARP10 (0.38) | PARP10PARP15HPGDSCN9APDE2A | |
| SCHEMBL16490706 | 0.88 | PARP10 (0.41) | PARP10PARP15HPGDSCN9APDE2A | |
| SCHEMBL15181006 | 0.84 | PARP10 (0.39) | PARP10PARP15HPGDSCN9APDE2A | |
| SCHEMBL17548060 | 0.83 | BACE1 (0.35) | PARP10PARP15HPGDSCN9APDE2A | |
| SCHEMBL17547988 | 0.83 | PARP10 (0.47) | PARP10PARP15HPGDSCN9A | |
| SCHEMBL31276 | 0.83 | PARP10 (0.38) | PARP10PARP15HPGDSCN9AKAT6A | |
| SCHEMBL10014161 | 0.80 | HPGD (0.39) | PARP10PARP15HPGDSCN9A | |
| SCHEMBL16590846 | 0.80 | PPARD (0.48) | PARP10PARP15HPGDSCN9A | |
| SCHEMBL17548019 | 0.79 | PARP10 (0.44) | PARP10PARP15HPGDSCN9A | |
| SCHEMBL19496733 | 0.79 | SCN9A (0.38) | PARP10PARP15HPGDSCN9APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170029698-A1 | ANTIOXIDANT FOR LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE USING LIQUID CRYSTAL COMPOSITION | DIC CORPORATION (JP) | 2017-02-02 | — | — | US | disclosed |
| US-9487704-B2 | Nematic liquid crystal composition and liquid crystal display element using same | DIC CORPORATION (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160319195-A1 | NEMATIC LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT USING THE SAME | DIC CORPORATION (JP) | 2016-11-03 | — | — | US | disclosed |
| US-20160060526-A1 | NEMATIC LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT USING SAME | DIC CORPORATION (JP) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029698-A1 | ANTIOXIDANT FOR LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE USING LIQUID CRYSTAL COMPOSITION | GPX1, LPO, SCO2 | PARP10 4296/4885PARP15 4768/4885HPGD 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.